ACIP: Guidance for Health Economics Studies

Print
Related Pages

These procedures should be followed for economic analyses to be presented to an ACIP Work Group or to the ACIP, effective as of the ACIP meeting of October 23-24, 2019.
Cost-effectiveness and other types of economic analyses are frequently presented during meetings of ACIP Work Groups (WGs) and the ACIP. The Guidance for Health Economics Studies Presented to the ACIP, 2019 Update (Guidance) was developed to ensure that economic data presented to the WGs and to the ACIP are uniform in presentation, understandable, and of the highest quality. The Guidance mandates a technical review of any economic study that is being considered for presentation. Economic study materials that are being submitted for review must include two items: (1) a document or report that describes the methods and results of the study, and (2) a slide set and/or other presentation materials.

The report and presentation materials must be submitted to the relevant ACIP WG Chair and CDC Lead staff person no later than 8 weeks before the presentation is to be made at an ACIP WG meeting.

Selected* publications of health economic modeling studies

Published cost effective analysis (CEA) studies
Vaccine MMWR publication date Vaccine recommendations published in MMWR Economic model publications
Pneumococcal September 2022 Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States
Hepatitis B April 2022 Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults
Zoster (Shingles) January 2022 Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years
Dengue December 2021 Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021 Cost-effectiveness of dengue vaccination in Puerto Rico
Tdap January 2020 Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019 Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States
Pneumococcal November 2019 Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program
Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions
HPV August 2019 Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States
Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model
Japanese Encephalitis July 2019 Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices Comparative economic analysis of strategies for Japanese encephalitis vaccination of U.S. travelers
Zoster (Shingles) January 2018 Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations
Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults
HPV December 2016 Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis
HPV March 2015 Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices Health and Economic Impact of Switching From a 4-Valent to a 9-Valent HPV Vaccination Program in the United States
The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model
Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine
Meningococcal March 2013 Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MCV vaccination in the presence of vaccine-associated Guillain–Barré Syndrome risk: A decision analysis approach
Pneumococcal October 2012 Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
HPV December 2011 Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males — Advisory Committee on Immunization Practices (ACIP), 2011 Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
The cost-effectiveness of male HPV vaccination in the United States
Tdap October 2011 Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged <12 Months — Advisory Committee on Immunization Practices (ACIP), 2011 Pregnancy Dose Tdap and Postpartum Cocooning to Prevent Infant Pertussis: A Decision Analysis
Meningococcal August 2007  Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11–18 Years with Meningococcal Conjugate Vaccine Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States
Varicella June 2007 Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP) An Economic Analysis of the Universal Varicella Vaccination Program in the United States
Cost-effectiveness of a Routine Varicella Vaccination Program for US Children
HPV March 2007 Quadrivalent human papillomavirus vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP) Cost-effectiveness of Human Papillomavirus Vaccination in the United States
Hepatitis A May 2006 Prevention of Hepatitis A Through Active or Passive Immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States
Meningococcal March 2005 Prevention and Control of Meningococcal Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP) Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysis
Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States
Should college students be vaccinated against meningococcal disease? A cost-benefit analysis

*The table does not include all publications of models presented to ACIP; e.g., industry/sponsor models are not included.

Top of Page